The University of Texas at San Antonio (UTSA) has opened its New Venture Incubator (NVI) — a facility with laboratory, office, and meeting spaces — to support technology start-ups in greater San Antonio. Housed on UTSA’s main campus, the NVI is designed to support companies that are commercializing UTSA IP or sponsoring research in the school’s labs. The incubator also is designed to fit into San Antonio’s broader technology commercialization environment as a source of new ventures. UTSA has established a Commercialization Council, which includes an influential group of top executives, to guide the NVI’s relationship to San Antonio’s entrepreneurial ecosystem. “The goal of the Commercialization Council is to develop the linkages between organizations that can play a key role in the region’s technology-based entrepreneurship,” says Cory Hallam, director of the UTSA Center for Innovation and Technology Entrepreneurship. “Ultimately, we want tech entrepreneurs to look at San Antonio the same way they look at Austin or Silicon Valley.”<\/p>\n
Currently, the Council includes representatives from UTSA, Southwest Research Institute, Southwest Foundation for Biomedical Research, San Antonio Technology Accelerator Initiative, Biomed SA, South Texas Technology Management, The Small Business Development Center, and AT&T. “UTSA recognizes the potential of establishing a campus-based technology incubator for San Antonio entrepreneurs that have direct ties to the university,” Hallam explains. “By working with promising new companies that are aligned with the university’s research strengths, we create a win-win partnership that benefits the university through increased research funding and IP licenses while providing start-ups with connections to the support they need to become successful freestanding enterprises.”<\/p>\n
Biopharmaceutical firm ViroXis Corp. will be the first start-up to occupy space in the NVI. The company aims to identify and patent botanically derived compounds for use in infectious disease and cancer therapies. Over the next two to three years, ViroXis will work to develop a rapid, cost-effective, and proven botanical prescription drug targeting human papillomavirus (HPV), which causes skin and genital wart infections and is the leading cause of cervical cancer.<\/p>\n
Source: Earth Times
\n <\/a><\/p>\n
\n4 Unique Royalty Rate References<\/strong><\/h2>\n |